I. Reijers

发表

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

K. Shannon, R. Scolyer, E. Rozeman, 2022, JAMA surgery.

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors

C. Blank, G. Long, P. Dimitriadis, 2022, Science Translational Medicine.

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins

Lauren E. Stopfer, C. Blank, S. Spranger, 2022, Journal for ImmunoTherapy of Cancer.

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

R. Sullivan, P. Ascierto, J. McQuade, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

P. Ascierto, C. Blank, G. Long, 2020 .

LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

R. Scolyer, S. Cornelissen, G. Long, 2021, Annals of Oncology.

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

K. Shannon, R. Scolyer, K. Sikorska, 2022, Nature Medicine.

Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma.

E. Rozeman, C. Blank, J. Haanen, 2018, Annals of Oncology.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

N. Ajami, K. Shannon, J. Wargo, 2022, Nature Medicine.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

A. Enk, B. Schilling, Douglas B. Johnson, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

P. Ascierto, Douglas B. Johnson, C. Blank, 2021, The Lancet. Oncology.

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma

E. Rozeman, C. Blank, J. Haanen, 2020, Pigment cell & melanoma research.

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

K. Sikorska, E. Rozeman, C. Blank, 2020 .

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, The Lancet. Oncology.

Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy

K. Shannon, J. Wilmott, R. Scolyer, 2020, Tumor Biology.

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

A. Broeks, R. Scolyer, D. Peeper, 2023, The Journal of experimental medicine.

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

A. Hauschild, K. Kähler, P. Ascierto, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

K. Shannon, A. Broeks, T. Schumacher, 2021, Nature Medicine.

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

B. Schilling, R. Scolyer, E. Rozeman, 2021, European journal of cancer.

3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

T. Schumacher, K. Sikorska, C. Blank, 2019, Annals of Oncology.

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

R. Scolyer, E. Rozeman, C. Blank, 2019, Journal of Clinical Oncology.

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.

A. Broeks, R. Scolyer, K. Sikorska, 2020 .

Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.

A. Broeks, R. Scolyer, O. Krijgsman, 2020 .

Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.

C. Blank, A. Hak, M. Hilhorst, 2020, Clinical and experimental rheumatology.

Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

A. Broeks, T. Schumacher, R. Scolyer, 2020 .

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

D. Schadendorf, R. Dummer, E. Rozeman, 2023, Cancer research communications.

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma

A. Broeks, G. Hospers, L. V. van de Poll-Franse, 2023, Nature medicine.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

P. Ascierto, G. Hospers, J. Haanen, 2024, The New England journal of medicine.